Prof. David Price, Prof. David Berg, Prof. Bartolome Celli, 20211111094400
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with increased mortality not only from respiratory failure, but also from cardiovascular (CV) events. At the European Respiratory Society (ERS) International Congress 2021, experts discussed a multidisciplinary approach to better protect patients with COPD from exacerbations and mortality. Professor David Price of the Observational and Pragmatic Research Institute, Singapore, outlined the burden of exacerbations and mortality in COPD. Dr David Berg of the Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, US, offered a cardiologist’s insight into COPD and CV risk. Professor Bartolome Celli of Harvard Medical School, Boston, Massachusetts, US, explored the role of triple therapy in reducing mortality risk in patients with COPD.
Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.
Treatment with MV130, a sublingual bacterial immunotherapy, reduces the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to a recent study presented at ERS 2021.
Infants born to mothers who were inactive during pregnancy were more likely to have low lung function compared with those whose mothers were active while pregnant, according to the PreventADALL study presented at ERS 2021.
The administration of inhaled budesonide for the treatment of early COVID-19 in adults reduced the probability of needing urgent medical care and time to recovery, according to findings from the STOIC* trial presented at ERS 2021.